• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

持续性幽门螺杆菌感染:对当前临床实践局限性的洞察

Persistent Helicobacter pylori Infection: An Insight to the Limitations of Current Clinical Practice.

作者信息

Liyen Cartelle Anabel, Uy Pearl Princess, Koehler Tara E, Yap John Erikson L

机构信息

Department of Medicine, Medical College of Georgia - Augusta University, Augusta, USA.

Gastroenterology and Hepatology, Medical College of Georgia - Augusta University, Augusta, USA.

出版信息

Cureus. 2020 Dec 26;12(12):e12309. doi: 10.7759/cureus.12309.

DOI:10.7759/cureus.12309
PMID:33520508
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7837641/
Abstract

The discovery of the pathological role of in various disease states, such as peptic ulcer disease (PUD) and Mucosa Associated Lymphoid Tissue (MALT) lymphoma, was ground-breaking in the field of gastroenterology. Given the potentially dire clinical implications of chronic infection, it is important to achieve complete eradication. More importantly, the rising prevalence of antimicrobial resistance, similar to other pathogens world-wide, is of particular concern. Despite evidence supporting the growing threat of antimicrobial resistance, clinically, it is also important to survey just how much of the failed treatment is truly a reflection of resistance versus poor treatment adherence. In this report, we detail the case of a 64-year-old female who was previously given six treatment courses for persistent infection. Successful eradication was achieved with rifabutin triple therapy consisting of high-dose amoxicillin and strict adherence monitoring by a clinical pharmacist. This case highlights the importance of patient education, medication reconciliation, and close monitoring to ensure successful treatment of persistent infection.

摘要

在各种疾病状态中,如消化性溃疡病(PUD)和黏膜相关淋巴组织(MALT)淋巴瘤,[病原体名称]病理作用的发现是胃肠病学领域的突破性进展。鉴于慢性[病原体名称]感染可能产生的严重临床后果,实现彻底根除至关重要。更重要的是,与世界其他病原体类似,[病原体名称]抗菌药物耐药性的日益普遍尤其令人担忧。尽管有证据支持抗菌药物耐药性构成的日益严重威胁,但在临床上,调查有多少治疗失败真正是由于耐药性而非治疗依从性差也很重要。在本报告中,我们详细介绍了一名64岁女性的病例,该女性此前因持续性[病原体名称]感染接受了六个疗程的治疗。通过由高剂量阿莫西林组成的利福布汀三联疗法以及临床药师的严格依从性监测,成功实现了根除。该病例凸显了患者教育、用药核对以及密切监测对于确保持续性[病原体名称]感染成功治疗的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4df/7837641/730c2ff76648/cureus-0012-00000012309-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4df/7837641/dbe03c409540/cureus-0012-00000012309-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4df/7837641/730c2ff76648/cureus-0012-00000012309-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4df/7837641/dbe03c409540/cureus-0012-00000012309-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4df/7837641/730c2ff76648/cureus-0012-00000012309-i02.jpg

相似文献

1
Persistent Helicobacter pylori Infection: An Insight to the Limitations of Current Clinical Practice.持续性幽门螺杆菌感染:对当前临床实践局限性的洞察
Cureus. 2020 Dec 26;12(12):e12309. doi: 10.7759/cureus.12309.
2
Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report.幽门螺杆菌感染管理的当前概念——《马斯特里赫特2-2000共识报告》
Aliment Pharmacol Ther. 2002 Feb;16(2):167-80. doi: 10.1046/j.1365-2036.2002.01169.x.
3
Novel and Effective Therapeutic Regimens for in an Era of Increasing Antibiotic Resistance.抗生素耐药性不断增加的时代下针对[具体病症,原文缺失]的新型有效治疗方案
Front Cell Infect Microbiol. 2017 May 5;7:168. doi: 10.3389/fcimb.2017.00168. eCollection 2017.
4
Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia.幽门螺杆菌根除治疗在消化性溃疡中比在非溃疡性消化不良中更有效。
Eur J Gastroenterol Hepatol. 2001 Nov;13(11):1303-7. doi: 10.1097/00042737-200111000-00007.
5
Outcomes of furazolidone- and amoxicillin-based quadruple therapy for infection and predictors of failed eradication.呋喃唑酮和阿莫西林四联疗法治疗感染的结果及根除失败的预测因素。
World J Gastroenterol. 2018 Oct 28;24(40):4596-4605. doi: 10.3748/wjg.v24.i40.4596.
6
The role of screening for Helicobacter pylori in patients with duodenal ulceration in the primary health care setting.在初级卫生保健机构中,对十二指肠溃疡患者进行幽门螺杆菌筛查的作用。
Br J Gen Pract. 1996 Mar;46(404):177-9.
7
[Helicobacter pylori eradication therapy in Korea].[韩国的幽门螺杆菌根除治疗]
Korean J Gastroenterol. 2011 Dec;58(2):67-73. doi: 10.4166/kjg.2011.58.2.67.
8
Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.基于利福布汀的三联疗法与高剂量双联疗法对甲硝唑和克拉霉素均耐药的幽门螺杆菌进行挽救治疗的随机试验。
Aliment Pharmacol Ther. 2006 Jul 15;24(2):395-403. doi: 10.1111/j.1365-2036.2006.02993.x.
9
Rifabutin-Based Triple Therapy (RHB-105) for Eradication: A Double-Blind, Randomized, Controlled Trial.利福布丁三联疗法(RHB-105)根除幽门螺杆菌:一项双盲、随机、对照试验。
Ann Intern Med. 2020 Jun 16;172(12):795-802. doi: 10.7326/M19-3734. Epub 2020 May 5.
10
Helicobacter pylori: A Review of Current Diagnostic and Management Strategies.幽门螺杆菌:当前诊断与管理策略综述。
Dig Dis Sci. 2020 Jul;65(7):1917-1931. doi: 10.1007/s10620-020-06193-7.

引用本文的文献

1
Repurposing FDA-Approved Agents to Develop a Prototype Shikimate Kinase (HPSK) Inhibitor: A Computational Approach Using Virtual Screening, MM-GBSA Calculations, MD Simulations, and DFT Analysis.重新利用美国食品药品监督管理局(FDA)批准的药物来开发一种原型莽草酸激酶(HPSK)抑制剂:一种使用虚拟筛选、MM-GBSA计算、分子动力学(MD)模拟和密度泛函理论(DFT)分析的计算方法。
Pharmaceuticals (Basel). 2025 Jan 27;18(2):174. doi: 10.3390/ph18020174.
2
Emergence of amoxicillin resistance and identification of novel mutations of the pbp1A gene in Helicobacter pylori in Vietnam.越南幽门螺杆菌中甲氧西林耐药的出现及 pbp1A 基因新突变的鉴定。
BMC Microbiol. 2022 Feb 3;22(1):41. doi: 10.1186/s12866-022-02463-8.
3

本文引用的文献

1
Clinical factors associated with initial Helicobacter pylori eradication therapy: a retrospective study in China.与初始幽门螺杆菌根除治疗相关的临床因素:中国的一项回顾性研究。
Sci Rep. 2020 Sep 21;10(1):15403. doi: 10.1038/s41598-020-72400-0.
2
Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics.在抗生素耐药性日益增加的时代,最近的幽门螺杆菌治疗指南的协调。
Gastroenterology. 2019 Jul;157(1):44-53. doi: 10.1053/j.gastro.2019.04.011. Epub 2019 Apr 15.
3
Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions.
Two rare cases of bronchus-associated lymphoid tissue lymphoma successfully treated with rituximab-bendamustine.
两例罕见的支气管相关淋巴样组织淋巴瘤经利妥昔单抗-苯达莫司汀成功治疗。
Clin Case Rep. 2021 Aug 6;9(8):e04557. doi: 10.1002/ccr3.4557. eCollection 2021 Aug.
幽门螺杆菌抗生素耐药性的流行情况:世界卫生组织区域的系统评价和荟萃分析。
Gastroenterology. 2018 Nov;155(5):1372-1382.e17. doi: 10.1053/j.gastro.2018.07.007. Epub 2018 Jul 7.
4
Inappropriate treatment in Helicobacter pylori eradication failure: a retrospective study.幽门螺杆菌根除失败的不恰当治疗:一项回顾性研究。
Scand J Gastroenterol. 2018 Feb;53(2):130-133. doi: 10.1080/00365521.2017.1413132. Epub 2017 Dec 7.
5
Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis.全球幽门螺杆菌感染率:系统评价和荟萃分析。
Gastroenterology. 2017 Aug;153(2):420-429. doi: 10.1053/j.gastro.2017.04.022. Epub 2017 Apr 27.
6
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.美国胃肠病学会临床指南:幽门螺杆菌感染的治疗
Am J Gastroenterol. 2017 Feb;112(2):212-239. doi: 10.1038/ajg.2016.563. Epub 2017 Jan 10.
7
Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.幽门螺杆菌感染的管理——马斯特里赫特 V/佛罗伦萨共识报告。
Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288. Epub 2016 Oct 5.
8
Helicobacter pylori infection: An overview of bacterial virulence factors and pathogenesis.幽门螺杆菌感染:细菌毒力因子与发病机制概述
Biomed J. 2016 Feb;39(1):14-23. doi: 10.1016/j.bj.2015.06.002. Epub 2016 Apr 1.
9
Improving compliance with helicobacter pylori eradication therapy: when and how?提高幽门螺杆菌根除治疗的依从性:何时及如何?
Therap Adv Gastroenterol. 2009 Sep;2(5):273-9. doi: 10.1177/1756283X09337342.
10
Management of Helicobacter pylori eradication--the influence of structured counselling and follow-up.幽门螺杆菌根除治疗的管理——结构化咨询与随访的影响
Br J Clin Pharmacol. 2002 Feb;53(2):163-71. doi: 10.1046/j.0306-5251.2001.01531.x.